Methods of treating blood disorders with vwf-targeted monospecific antibodies
EP4762096A1Pending Publication Date: 2026-06-24HEMAB APS
Patent Information
- Authority / Receiving Office
- EP · EP
- Patent Type
- Applications
- Current Assignee / Owner
- HEMAB APS
- Filing Date
- 2024-08-16
- Publication Date
- 2026-06-24
AI Technical Summary
Technical Problem
Current treatments for blood disorders related to von Willebrand factor (VWF) are inadequate in effectively managing the condition.
Method used
Development of monospecific antibodies specifically designed to target the VWF protein, leading to its accumulation in blood plasma.
Benefits of technology
The antibodies effectively accumulate VWF in blood plasma, potentially improving treatment outcomes for blood disorders associated with VWF.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure EP2024073157_20022025_PF_FP_ABST
Abstract
Provided herein are antibodies, compositions, and methods of use thereof. The disclosed antibodies bind to von Willebrand factor in blood plasma of a subject. Such antibodies are useful for methods of treatment, such methods of treating one or more blood disorders characterized by excessive bleeding.
Need to check novelty before this filing date? Find Prior Art